



Designing PV Systems for Humans and Agentic AI


Responsible system design for agentic AI in
regulated Pharmacovigilance

Malin Kreitz
Ultragenic Research & Technologies
Switzerland



The Reality of Pharmacovigilance in 2026


AI adoption is being pushed faster than PV system evolution



The Core Problem: An Architectural Mismatch

AI is not being integrated into purpose-built systems —

AI is retrofitted into systems designed solely for human interaction




Design Principle: Systems for Humans AND Agentic AI

AI should be treated as a system actor, not an external tool

Future PV systems will have dual primary actors



Human Experts
(Medical, Safety, QA)



Agentic AI Components


- Structured data access and orchestration required
- Interpretable outputs for both humans and regulators
- Native integration instead of bolt-on automation layers

Understanding HITL vs HOTL

The objective is not to replace humans, but to reposition them

Human-in-the-Loop (HITL): The Expert

- Executes and validates operational steps
- High manual interaction
- Suitable for high-risk and novel processes



Human-on-the-Loop (HOTL): The Supervisor

- Humans supervise and govern AI-driven workflows
- Exception-based intervention
- Focus on high-value oversight and decision-making





Image Source: Springer

When HITL fails: The Risk of the “Complicit Human”


Poor HITL design creates passive confirmation rather than true oversight



- Meaningful review interfaces instead of checkbox validation
- Explainable AI outputs with rationale visibility
- Risk-based review triggers with differentiation between routine and critical cases
- Clear confidence scores and uncertainty indicators

Building Trust: A Risk-Based Path from HITL to HOTL

Trust in AI systems must be earned through transparency, performance and auditability



Established trust does not end monitoring
– models can deteriorate and more adapted ones released

Alignment with CIOMS Principles: Fairness and Equity

Fairness and equity are system design responsibilities, not just model features

Ensuring Responsible AI in Pharmacovigilance




Image source: CIOMS

- Potential Risks in PV AI Systems: - Language bias in case intake - Regional reporting disparities - Training data imbalance - Underrepresentation of specific populations
- Design Safeguards: - Diverse and representative datasets - Bias monitoring and fairness audits - Human review for sensitive classifications - Transparent documentation of model limitations

Continuous Model Evaluation & Future-Proof PV Architecture

AI models evolve rapidly — PV systems must continuously evaluate, replace and govern them



WHY THIS MATTERS

- Rapid evolution of AI models
- Regulatory expectations for validated performance
- Need for ongoing benchmarking and monitoring



CONTINUOUS MODEL EVALUATION

- Performance tracking over time
- Benchmarking against emerging models
- Audit logs for model decisions
- Controlled model replacement processes




FUTURE-PROOF PV ARCHITECTURE

- Model-agnostic architecture
- Modular system design
- Interoperable AI components
- Native auditability & traceability
- Governance-by-design approach

Future-ready PV platforms must be flexible, explainable, auditable — and able to safely integrate better models as they emerge.


Strategic Implications for PV Organisations

Transformation is a System Design, not only a Technology Adoption Challenge




The Future is Human-on-the-Loop


Take-Away Messages




The future of PV systems is **hybrid** where **humans** remain informed, **in control**, and supervising transparent and **trustworthy** AI-driven workflows, paired with the **responsible** usage of **AI**




AI will not fix poorly designed processes / systems




Just because you *can* use AI does not mean you *should*



Human expertise remains central in regulated PV



Trustworthy AI requires transparency, fairness, and continuous evaluation



Risk-based transition from HITL to HOTL is essential

Thank You!

Let's Redefine the Future of Drug
Safety - Together.

Contact us at contactus@ultragenicglobal.com

Leveraging Technology Advancing Outcomes

HQ - India

Ultragenic Research & Technologies
Delhi / Noida

Japan

Ultragenic Research & Technologies KK
Tokyo

US

Ultragenic Research & Technologies LLC
Baskin Ridge, NJ

Switzerland

Ultragenic Research & Technologies GmbH
Basel

China

Ultragenic Research & Technologies
Shanghai